Skip to content

Pathogenic gene screening and study of serum iFGF-23 in X linked hypophosphatemia rickets or osteomalacia

Pathogenic gene screening and study of serum iFGF-23 in X linked hypophosphatemia rickets or osteomalacia

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200058016
Enrollment
Unknown
Registered
2022-03-26
Start date
2022-04-30
Completion date
Unknown
Last updated
2023-11-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

X linked hypophosphatemia rickets or osteomalacia

Interventions

case series:None

Sponsors

Shanghai Sixth People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
No minimum to 100 Years

Inclusion criteria

Inclusion criteria: 1. The patient is highly suspected to be X-linked dominant hypophosphate rickets/osteomalacia, with unexplained lower extremity deformities, gait abnormalities, bone pain, lower extremity weakness, difficulty walking, limited joint mobility, abnormal bone density, and abnormal tooth development; 2. The patient had growth and development delay in the past, was significantly lower in height than her peers or had abnormal body proportion (compared with the upper lower volume of the same age); 3. The patient has an obvious family history or is the offspring of inbreeding, and the disease starts at an early age; 4. The patient had obvious biochemical abnormalities, such as blood phosphorus lower than the normal reference value of peers, or (and) imaging examination showed abnormal bone development, such as knee varus or eversion, false fracture line, etc.; 5. Patients sign informed consent in person, indicating that they have been informed of all the content related to the study; 6. Patient is willing and able to comply with study visit arrangements, laboratory examinations, and other study procedures.

Exclusion criteria

Exclusion criteria: 1. Patients or their guardians refuse to take blood samples; 2. Using alcohol and/or mentally active drug, drug abuse and dependence; 3. Other patients considered unsuitable for the study by the researcher.

Design outcomes

Primary

MeasureTime frame
Fibroblast growth factor 23;

Countries

China

Contacts

Public ContactZhang Zhenlin
zzl2002@medmail.com.cn+86 13621673716

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026